SalubrisBio parent company Salubris Pharmaceuticals announces investment of $5M in GO Therapeutics (Cambridge, USA) to support development of their novel microinjection platform technology
By: jonadmin|Published on: Oct 27, 2020|Categories: |
By: jonadmin|Published on: Oct 27, 2020|Categories: |
Recent Comments